FDA Updates News 25 November 2025

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson (NYSE: JNJ) shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ

16 December 2025

FDA Updates·Financial Analysis·Investing·Pharma News·Stock Market

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025,

15 December 2025

FDA Updates·Legal News·Pharmaceuticals·Stock Market

Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching

Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is stepping into December 15, 2025 with a very “micro-cap biotech” mix of catalysts and pressure points: a Nasdaq deadline calendar, an FDA regulatory milestone for its lead sublingual aspirin program, and capital-structure dynamics

15 December 2025

FDA Updates·Investment Risks·Stock Market

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock (LSE: GSK, NYSE: GSK) is ending 2025 with a rare “cluster” of market-moving catalysts

15 December 2025

FDA Updates·Investment Analysis·Pharma News·Stock Market

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

Updated: Sunday, December 14, 2025 (markets closed; prices reflect the most recent close). GSK plc (LSE: GSK / NYSE: GSK) heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion

14 December 2025

Earnings Reports·FDA Updates·Investment News·Pharmaceuticals·Stock Market

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil)

12 December 2025

FDA Updates·Investment Analysis·Market News·Pharmaceuticals·Stocks

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing,

11 December 2025

FDA Updates·Healthcare Industry·Investment Outlook·Market News

Ascendis Pharma (ASND) Stock Slides After Q3 Miss and FDA Delay – What Investors Need to Know on December 9, 2025

Ascendis Pharma A/S (NASDAQ: ASND) is back in the spotlight on December 9, 2025, after its share price slipped again while Wall Street continues to project hefty upside and label the name a “Buy” or “Strong Buy.” The Danish biotech,

9 December 2025

Earnings Reports·FDA Updates·Investment Analysis·Pharma News·Stock Market

GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts

As of December 3, 2025, GSK plc (LSE:GSK, NYSE:GSK) is trading near multi‑year highs after a year of earnings beats, a revived oncology franchise, heavy share buybacks and an unusually busy FDA calendar for December. At the same time, analysts

3 December 2025

FDA Updates·Investment Strategies·Market Forecasts·Pharma News·Stock Analysis

Pfizer (PFE) Stock on December 2, 2025: Price, Metsera Deal, New FDA Risks and 2026 Outlook

As of late trading on Tuesday, December 2, 2025, Pfizer (NYSE: PFE) shares change hands around $25.10, down roughly 0.7% on the day and sitting in the middle of their 52‑week range of $20.92–$27.69. Yahoo Finance The stock carries a dividend yield

2 December 2025

FDA Updates·Investment Outlook·Pfizer News·Pharma Industry·Stock Analysis

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc. (NYSE: ABBV) heads into the final month of 2025 with a mixed but generally constructive backdrop for shareholders. The stock is trading in the mid‑$220s per share — around $227 — implying a market capitalization of roughly $400

30 November 2025

Dividends·FDA Updates·Investment Strategies·Pharma News·Stock Analysis

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and

25 November 2025

Biotech Stocks·FDA Updates·Stock Market News

FDA Updates News 25 November 2025 - 16 December 2025